MENU

ICCC Stock ImmuCell (ICCC, $5.92) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 12, 2025

A.I.dvisor
at Tickeron.com
Loading...
ICCC - ImmuCell Corp
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $5.92
Daily change: -$0.21 (-3.43%)
Daily volume: 6.8K
Capitalization: $53.6M
Industry: Biotechnology
This is a Bearish indicator signaling ICCC's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 48 similar cases where ICCC's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

ICCC sees MACD Histogram crosses below signal line

ICCC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 12, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ICCC as a result. In of 121 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ICCC moved below its 50-day moving average on September 09, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ICCC entered a downward trend on September 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.787) is normal, around the industry mean (20.607). P/E Ratio (28.095) is within average values for comparable stocks, (53.283). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.160). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (1.832) is also within normal values, averaging (333.412).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a developer of products for cattle health

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
56 Evergreen Drive
Phone
+1 207 878-2770
Employees
79
Web
https://www.immucell.com